BioCentury
ARTICLE | Financial News

Nextbiotix raises EUR7M series A round to bring IBD therapy into clinic

July 13, 2018 7:58 PM UTC

Microbiome company Nextbiotix S.A.S. (Dijon, France) raised €7 million ($8.1 million) in a series A round led by new investor Auriga Partners. Fellow new investors Sofimac Innovation, Cap Innov'Est, INRA and Biocodex also participated.

Nextbiotix spokesperson Bruno Arabian told BioCentury the company expects to begin clinical testing of lead candidate NBX1650 in about two years for an undisclosed inflammatory bowel disease indication...

BCIQ Company Profiles

Exeliom Biosciences S.A.S.